# Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.

Study · id `cardio:ct-nct04858308` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04858308](<https://clinicaltrials.gov/study/NCT04858308>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04858308

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 554 participants.

## Technical summary

Registry record NCT04858308. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-29 (actual); primary completion 2021-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 554 participants (planned count; ClinicalTrials.gov record NCT04858308, source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)
- Started: 2021-01-29 (actual) (ClinicalTrials.gov record NCT04858308, source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)
- Primary completion: 2021-05-31 (anticipated) (ClinicalTrials.gov record NCT04858308, source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)
- Completion: 2022-01-31 (anticipated) (ClinicalTrials.gov record NCT04858308, source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT04858308, source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04858308-2021-04-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.
- Acronym: Atorf-YOOrct
- Condition: Dyslipidemias
- Intervention (Drug): YYC506
- Intervention (Drug): Control
- Intervention (Drug): YYC506 Placebo
- Intervention (Drug): Control Placebo
- Lead sponsor: Yooyoung Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 09fa0ec813401058d962739ce919307f15c6daae66baa86ba8e8bc1440a4bdcf
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
